NASDAQ · CRONHealthcarePharmaceuticals

Cronos Group Inc. Common Share financials

$3.38−0.88%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$193.4M$161.8M$120.3M$86.7M$64.6M$46.7M$23.8M$12.1M
Gross profit$110.2M$70.1M$45.7M$15.4M-$17.6M-$25.8M-$17.6M$6.2M
Gross margin57.0%43.3%38.0%17.8%−27.3%−55.3%−74.1%51.3%
Operating income-$17.4M-$102.2M-$108.2M-$111.4M-$292.0M-$219.4M-$153.3M-$20.4M
Net income-$9.4M$41.1M-$74.0M-$168.7M-$396.1M-$73.1M$1.17B-$21.6M
Net margin−4.9%25.4%−61.5%−194.5%−613.5%−156.5%4911.6%−178.5%
Diluted EPS$-0.02$0.11$-0.19$-0.45$-1.07$-0.21$3.33$-0.12
EBITDA-$391.0K-$50.2M-$71.8M-$91.3M-$150.1M-$172.3M-$143.7M-$18.5M
Operating cash flow$25.9M$18.8M-$42.8M-$88.9M-$153.6M-$144.9M-$131.2M-$7.5M
Free cash flow$149.0K$6.4M-$45.3M-$92.4M-$164.8M-$176.3M-$169.9M-$95.8M
Diluted shares383.5M385.6M381.0M377.0M370.4M351.6M342.8M172.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$791.8M$858.8M$669.3M$764.6M$887.0M$1.08B
Short-term investments$40.0M$0.00$192.2M$113.1M$117.7M$211.8M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$1.20B$1.17B$1.14B$1.21B$1.40B$1.93B
Total liabilities$54.2M$55.3M$44.1M$72.0M$63.5M$217.5M
Shareholders' equity$1.14B$1.11B$1.10B$1.14B$1.33B$1.71B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology